Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07646197

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.

* Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available

Recruiting

Interested in participating?

Request Info

Key information

Conditions

MASLD Digestive System Diseases Fatty Liver Liver Diseases

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Henry Ford Health System

Detroit, Michigan, 48202, United States

Location status: Recruiting

Location contact

Menghua Tao, Ph.D.

CONTACT

[email protected]

3138768471

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 30-70 years
  • do not consume peanut/peanut butter/treenut/seeds > /week
  • at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
  • Able to understand, speak, and read English
  • Mentally competent to consent

Exclusion criteria

  • Food allergy to peanuts or peanut-containing products
  • With alcohol use disorder (AUDIT screening)
  • Leukemia
  • Lymphoma
  • Other types of cancer
  • Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
  • Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)

Treatment and study plan

Peanut consumption

Other

MASLD patients will consume 50 gm of peanut daily for 12 weeks

Primary outcomes

  1. Hepatic Markers

    Time frame: Baseline to post-intervention (12 weeks)

    Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention

Secondary outcomes

  1. Metabolic Profile

    Time frame: Baseline to post-intervention (12 weeks)

    Investigate change in metabolic profiles i.e., total cholesterol, HDL-C, LDL-C, triglycerides, glucose, hemoglobin A1C (HBA1C), and insulin over 12 weeks

  2. Gut microbiota composition

    Time frame: Baseline to post-intervention (12 weeks)

    Investigate whether MASLD patients in the Peanut arm will have improved gut microbiota compositions than those in the Control arm

  3. Intrahepatic fat content

    Time frame: Baseline to post-intervention (12 weeks)

    Explore whether MASLD patients in the Peanut arm may have lower intrahepatic fat content (IHF) than those in the Control arm over 12 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Menghua Tao, PhD

CONTACT

[email protected]

313-590-9408

Sponsors and collaborators

Lead sponsor

Henry Ford Health System

Other

Registry information

Official study title

Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 12, 2026
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.